Table 4

Associations between reflux symptoms and respiratory outcomes in atopic and non-atopic Study members.


Heartburn
Regurgitation
Heartburn and Regurgitation


Non-atopic
Atopic

Non-atopic
Atopic

Non-atopic
Atopic




OR (95% CI)
OR (95% CI)
p-itn
OR (95% CI)
OR (95% CI)
p-itn
OR (95% CI)
OR (95% CI)
p-itn


Asthma
1.81 (0.64, 5.17)
1.96 (1.12, 3.44)
0.873
4.03 (1.11, 14.5)
2.54 (1.23, 5.24)
0.603
3.51 (0.80, 15.3)
3.16 (1.35, 7.38)
0.827
Wheeze
2.88 (1.40, 5.90)
1.30 (0.76, 2.20)
0.072
7.27 (2.23, 23.7)
1.93 (0.95, 3.93)
0.062
6.56 (1.68, 25.6)
2.54 (1.07, 6.00)
0.253
Cough
4.67 (1.98, 11.0)
1.46 (0.73, 2.92)
0.039
5.90 (1.94, 18.0)
2.88 (1.30, 6.38)
0.315
10.8 (3.02, 38.6)
2.87 (1.12, 7.34)
0.099
BDR
2.81 (0.70, 11.3)
2.08 (0.99, 4.36)
0.760
7.57 (1.76, 32.5)
1.76 (0.64, 4.86)
0.108
12.7 (2.71, 59.6)
2.08 (0.67, 6.50)
0.067











Coeff (95% CI)
Coeff (95% CI)

Coeff (95% CI)
Coeff (95% CI)

Coeff (95% CI)
Coeff (95% CI)



FEV1/FVC
0.80 (-1.24, 2.84)
-1.15 (-3.13, -0.82)
0.213
-2.43 (-5.37, 0.51)
-2.27 (-4.95, 0.41)
0.940
-1.91 (-5.34, -1.51)
-2.56 (-5.79, 0.66)
0.808

Non-atopic groups (n = 278) and atopic (n = 536) defined by skin-prick tests at age 21. The FEV1/FVC ratio is analysed by linear regression. All other analyses use logistic regression. Analyses use the respiratory outcomes as the dependent variables and are adjusted for BMI and sex. OR = odds ratio, Coeff = coefficient, 95% CI = 95% confidence intervals, p-itn = p value for interaction between atopic status and reflux symptoms, BDR = 10% or greater increase in FEV1 following salbutamol.

Hancox et al. Respiratory Research 2006 7:142   doi:10.1186/1465-9921-7-142